What is the rating for ALNY stock?

ALNYLAM PHARMACEUTICALS, INC. (ALNY) has a "Hold" rating based on our 6-factor quantitative model. It has a composite score of 51.6 and ranks #1764 out of 7,333 stocks in our coverage universe with a 3-star rating.

Is ALNY a good stock to buy?

Based on our quantitative analysis, ALNY receives a "Hold" rating with 3 out of 5 stars. Key factors include: Quality score of 65.1, Value score of 58.6, and Momentum score of 43.5. The timing score is 51, indicating "Neutral" entry conditions. This is not investment advice - please conduct your own research.

What sector is ALNY in?

ALNYLAM PHARMACEUTICALS, INC. (ALNY) operates in the Manufacturing sector, specifically in the Pharmaceutical Products industry. It has a market capitalization of $59.77 billion.

What is ALNY's P/E ratio?

ALNY has a P/E (Price-to-Earnings) ratio of 810.87x. This helps investors assess whether the stock is trading at a premium or discount relative to its earnings.

Does ALNY pay a dividend?

ALNY does not currently pay a dividend.

What is ALNY's market cap?

ALNYLAM PHARMACEUTICALS, INC. (ALNY) has a market capitalization of $59.77 billion, making it a large-cap stock.

What are the risks of investing in ALNY?

Key risk factors for ALNY include: elevated debt levels, and general market risk. As with all investments, there is risk of loss.

How does ALNY compare to peers?

Within the Manufacturing sector, ALNY ranks #1764 overall with a quality score of 65.1/100 and value score of 58.6/100.

What is ALNY's revenue growth?

ALNY has revenue growth of 89.3% year-over-year.

What is ALNY's composite score?

ALNYLAM PHARMACEUTICALS, INC. (ALNY) has a composite score of 51.6/100, which places it at rank #1764 out of 7,333 stocks. This score is derived from our proprietary 6-factor quantitative model that evaluates quality, value, momentum, investment efficiency, stability, and short interest.

How does ALNY compare to the S&P 500?

ALNY ranks in the top 76% of all stocks in our coverage universe with a composite score of 51.6.

What are the bull and bear cases for ALNY?

Bull case: ALNY scores highest in stability at 71.8/100, indicating strong performance in this area. Bear case: The weakest factor is investment efficiency at 32.6/100, which may present a risk. Our overall assessment is Hold with 3 out of 5 stars.

Is ALNY overvalued or undervalued?

ALNY appears fairly valued with a value factor score of 58.6/100.

What is ALNY's momentum score?

ALNY has a momentum score of 43.5/100, placing it in the moderate category.

When is ALNY's next earnings date?

For the latest earnings date and analysis for ALNY, visit our earnings calendar or check the ALNY stock page for real-time updates. Our AI-generated earnings reports provide in-depth analysis after each quarterly report.

Is ALNY a good stock to buy right now?

Based on our 6-factor quantitative model, ALNYLAM PHARMACEUTICALS, INC. (ALNY) receives a "Hold" rating with a composite score of 51.6/100. It is ranked #1764 out of 7,333 stocks. Key factor scores: Quality 65/100, Value 59/100, Momentum 44/100. The timing signal is "Neutral". This is quantitative analysis only — not investment advice.

What is the stock rating for ALNY?

ALNYLAM PHARMACEUTICALS, INC. (ALNY) has a "Hold" rating and 3-star score. The composite score of 51.6 ranks it #1764 among 7,333 U.S. stocks. Ratings are updated weekly using academically-proven factor models.

What sector is ALNY in?

ALNYLAM PHARMACEUTICALS, INC. operates in the Manufacturing sector (Pharmaceutical Products industry) with a market cap of $59.77 billion. It is classified as a large-cap stock.

Does ALNY pay a dividend?

ALNY does not currently pay a regular dividend. The company may be reinvesting profits for growth.

What is ALNY's P/E ratio?

ALNY has a trailing P/E ratio of 810.87x. The Manufacturing sector average is 22.3x. This above-average P/E reflects growth expectations or premium valuation.

How profitable is ALNY?

ALNY's quality factor score is 65/100. Gross margin: 84.4%. ROE: 7.0% vs sector average -1.9%. High margins suggest pricing power and competitive moats.

How is ALNY valued compared to peers?

ALNY's value factor score is 59/100 (higher = cheaper). Key multiples: P/E 810.9x, EV/EBITDA 152.2x. Valuation is roughly in line with peers.

What is ALNY's debt level?

ALNY's debt-to-equity ratio is 529%. Sector average: 0%. Elevated leverage increases credit risk.

ALNY has a beta of 0.87, meaning it tracks the market. Stability score: 72/100.

Does ALNY have high short interest?

ALNY's short interest factor score is 56/100 (higher = less short selling). Moderate short interest.

ALNY Stock Analysis — ALNYLAM PHARMACEUTICALS, INC. Price Target & Forecast 2026

IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.

HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.

RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.

ALNY Stock Analysis — ALNYLAM PHARMACEUTICALS, INC. Price Target & Forecast 2026 | Blank Capital Research

Sector

Manufacturing

Industry

Pharmaceutical Products

Market Cap

$59.8B

Leadership

Yvonne L. Greenstreet

Business Summary

Alnylam Pharmaceuticals, Inc. focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS/ocular) diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

Operations

Headcount

2.0K

Location

HQ Base

CAMBRIDGE, Massachusetts

Fundamental Spot Check

Context: 2025

Valuation

Market Cap

$59.8B

P/E Ratio

810.9xLagging

P/B Ratio

56.50xLagging

P/S Ratio

14.30xLagging

EV/EBITDA

152.2xLagging

Dividend Yield

0.00%

Efficiency & Risk

Gross Margin

84.4%Outperforming

Operating Margin

3.8%Outperforming

ROE

7.0%Outperforming

Rev Growth (YoY)

89.3%

Debt/Equity

529.00xLagging

Beta

0.87

Red = Sector Laggard

Black = Market Average

Revenue Breakdown

Strategic Timing Audit

CAUTION

2/6

Mixed Alignment [2 BULL / 1 BEAR]

Quantitative Factor Convergence Analysis Verified

Momentum

44th pctl

Intelligence Feed

BCR INTELLIGENCEFeb 16 Analyst View

ALNYLAM PHARMACEUTICALS, INC. (ALNY) Is Wall Street's Safest Bet. What Could Go Wrong?

About ALNYLAM PHARMACEUTICALS Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of

yahooYesterday Positive

Alnylam to Webcast Presentation at TD Cowen 46th Annual Health Care Conference

CAMBRIDGE, Mass., February 23, 2026--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the TD Cowen 46th Annual Healthcare Conference on Monday, March 2, 2026 at 9:10 am ET.

insidermonkey.com4d ago Positive

Alnylam Pharmaceuticals (ALNY) Reports $3B 2025 Revenue Driven by 151% TTR Franchise Surge

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) is one of the best NASDAQ growth stocks to buy for the next 2 years.

BenzingaJan 2 Positive

This AI Infrastructure Stock Is 'Most Likely' To Be Added To S&P 500 In Q1 2026 According To Prediction Markets

Vertiv Holdings, an AI infrastructure company providing data center power and cooling solutions, has a 71% probability of being added to the S&P 500 in Q1 2026 according to prediction markets, significantly higher than competitors. The company has surged over 1,047% in less than three years with strong financial performance, including 29% year-over-year revenue growth and a robust $9.5 billion backlog.

yahoo10h ago Negative

GSK Strikes $1 Billion China RNA Deal

Frontier Pact Adds Genetic Drug Optionality

Earnings Call Transcripts

Unlock Valuation Tools

Get full access to institutional-quality research tools with Blank Capital Pro.

Upgrade to Pro

Starting at $19.99/mo

Financial Intelligence Ledger

Verified SEC Filings Aggregate • ALNY

Export

Metric Entity	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
Revenue	$3.7B65.2%	$2.2B23.0%	$1.8B76.2%	$1.0B22.9%	$844M71.3%	$493M124.3%	$220M193.4%	$75M16.7%	$90M90.7%	$47M
Cost of Revenue	$677M120.9%	$307M14.3%	$268M91.3%	$140M21.9%	$115M47.3%	$78M211.4%	$25M	$2M	$0	$0
Gross Profit	$3.0B56.4%	$1.9B24.5%	$1.6B73.9%	$897M23.0%	$729M75.8%	$415M113.1%	$195M166.3%	$73M18.7%	$90M90.7%	$47M
R&D Expense	$1.3B17.2%	$1.1B12.1%	$1.0B13.7%	$883M11.5%	$792M21.0%	$655M0.0%	$655M29.6%	$505M29.4%	$391M2.2%	$382M
Operating Expenses	$2.5B19.7%	$2.1B15.0%	$1.8B9.5%	$1.7B17.0%	$1.4B15.7%	$1.2B9.6%	$1.1B27.7%	$888M50.5%	$590M25.1%	$472M
Operating Income	$502M383.6%	-$177M37.3%	-$282M64.1%	-$785M10.8%	-$709M14.5%	-$828M11.8%	-$939M15.3%	-$815M62.9%	-$500M17.8%	-$425M
Interest Expense	—	—	$121M22.3%	$156M9.1%	$143M69.3%	$84M	$0	—	—	—
Tax Provision	$9M109.5%	-$99M	$7M61.5%	$4M512.2%	$680K74.6%	$3M210.7%	$863K4.9%	$823K	$0	—
EBITDA	$502M383.6%	-$177M37.3%	-$282M64.1%	-$785M10.8%	-$709M1.7%	-$697M19.4%	-$864M11.6%	-$775M57.7%	-$491M21.8%	-$403M
Net Income	$314M212.8%	-$278M36.8%	-$440M61.1%	-$1.1B32.6%	-$853M0.6%	-$858M3.1%	-$886M16.4%	-$761M55.1%	-$491M19.7%	-$410M
EPS (Diluted)	$2.39209.6%	$-2.1838.1%	$-3.5262.2%	$-9.3029.2%	$-7.203.5%	$-7.468.0%	$-8.117.1%	$-7.5739.7%	$-5.4213.2%	$-4.79

SEC EDGAR Repository

Direct unfiltered access to 10-K, 10-Q and 8-K filings for ALNY.

Open Regulatory Dossier

Data Integrity Notice

Figures adjusted for stock splits and restatements where applicable.

TTM (Trailing Twelve Months) data updates within 48 hours of quarterly filings.

Execution Benchmarks Audit

Revenue Growth

YOY expansion rate

+1241% SCTR

89.3%

Sector Avg: 6.7%

Gross Margin

Core pricing power

+92% SCTR

84.4%

Sector Avg: 44.1%

Operating Margin

Operating efficiency

+50% SCTR

3.8%

Sector Avg: 2.5%

Return on Equity

Equity efficiency

-467% SCTR

7.0%

Sector Avg: -1.9%

Debt/Equity

Financial leverage

-251805% SCTR

529.0%

Sector Avg: 0.2%

Dividend Yield

Direct cash return

-NaN% SCTR

0.0%

Sector Avg: 0.0%

Financial History

Forensic Accounting Audit

Audit Required

Earnings Qualityhigh RISK

Net income exceeding cash flow (Accrual bloat detected)

Asset Efficiency

Improving capital utilization rates confirmed

Margin Integritymedium RISK

High margin volatility — erratic forensic earnings quality

Algorithmic red flag detection based on regulatory SEC filings.

Unlock Financial Statements

Get full access to institutional-quality research tools with Blank Capital Pro.

Upgrade to Pro

Starting at $19.99/mo

Shareholder Returns

Capital Allocation audit

Smart Money Conviction

Neutral

Synthesized from recent 13F filings, Form 4 insider transactions, and outstanding short interest metrics.

Governance Audit

Moderate Index

WeakModerateStrong

Average governance indicators based on financial metrics. Verified against factor-based integrity benchmarks.

Executive Operations

CEO: Yvonne L. Greenstreet

Insider alignment Audit

No recent insider transactions available for ALNY

Major Institutional Blocks

Top 5 Holders

Institutional cap table data requires verified 13F filing feeds.

Access SEC 13F Dossier →

Form 4 Filings

Recent Activity

Insider transaction data currently awaiting regulatory verification.

Access SEC Form 4 Dossier →

Regulatory Disclosure Vault

Proxy Statement (DEF 14A)

Exec Comp, Board Nominees, Proposals

Annual Report (10-K)

MD&A, Risk Factors, Strategy

Institutional Holders (13F)

Loading institutional data...

Unlock Governance & Ownership

Get full access to institutional-quality research tools with Blank Capital Pro.

Upgrade to Pro

Starting at $19.99/mo

Unlock Factor Analysis

Get full access to institutional-quality research tools with Blank Capital Pro.

Upgrade to Pro

Starting at $19.99/mo

Unlock Investment Thesis

Get full access to institutional-quality research tools with Blank Capital Pro.

Upgrade to Pro

Starting at $19.99/mo

Institutional Peer Matrix

Top Manufacturing Universe

Stock	Rating	Score▼	Quality	Value	Momentum	P/E	EV/EBITDA	ROE	ROA	Gross Mgn	Op Mgn	Net Mgn	Rev Growth	Div Yield	D/E	Mkt Cap	AUDIT
$UL UNILEVER PLC		78	96	98	59	-	-	-	-	-	-	-	-	-	-	$0	VS
$ASML ASML HOLDING NV		77	89	86	83	-	-	-	-	-	-	-	-	-	-	$0	VS
$ESLT ELBIT SYSTEMS LTD		76	81	87	85	-	-	-	-	-	-	-	-	-	-	$0	VS
$MT ArcelorMittal		75	71	98	85	-	-	-	-	-	-	-	-	-	-	$0	VS
$AMAT APPLIED MATERIALS INC /DE		75	85	87	84	20.9x	13.6x	32.9%	20.5%	48.8%	30.6%	24.4%	7.7%	0.9%	32.0x	$148.6B	VS
$SIMO Silicon Motion Technology CORP		75	84	86	85	-	-	-	-	-	-	-	-	-	-	$0	VS
$CODA Coda Octopus Group, Inc.		74	83	90	79	16.3x	11.9x	7.4%	7.5%	68.3%	19.5%	18.2%	29.0%	0.0%	0.0x	$84M	VS
$GSK GSK plc		74	84	90	70	-	-	-	-	-	-	-	-	-	-	$0	VS
$EFXT Enerflex Ltd.		74	80	91	83	-	-	-	-	-	-	-	-	-	-	$0	VS
$BUD Anheuser-Busch InBev SA/NV		74	84	97	63	-	-	-	-	-	-	-	-	-	-	$0	VS
$ALNY ALNYLAM PHARMACEUTICALS, INC.		52	65	59	44	810.9x	152.2x	7.0%	1.1%	84.4%	3.8%	-3.5%	89.3%	0.0%	529.0x	$59.8B
SECTOR BENCH	-	-	-	-	-	22.3x	11.5x	-1.9%	0.9%	44.1%	2.5%	1.0%	6.7%	0.0%	0.2x	-	REF

Access Full Manufacturing Intelligence Archive →

Lateral Comparison Mesh

$ALNY / $UL AUDIT $ALNY / $ASML AUDIT $ALNY / $ESLT AUDIT $ALNY / $MT AUDIT $ALNY / $AMAT AUDIT

Market Intelligence FAQ

ALNYLAM PHARMACEUTICALS, INC. (ALNY) receives a "Hold" rating with a composite score of 51.6/100. It ranks #1764 out of 7,333 stocks in our coverage universe and carries a 3-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.

Full Research Publication

Equity Research Analysis: ALNYLAM PHARMACEUTICALS, INC. (ALNY)

FEBRUARY 2026|Blank Capital Research Unit|Spot: $332.80

Price$332.80

Composite Score51.6/100

RatingHOLD (3★)

Rank#1764 OF 7,333

Market Cap$59.8B

Comments

Institutional Audit

Feb 25, 2026

ALNYLAM PHARMACEUTICALS, INC.

51.6

Sector Decomposition auditManufacturing [N=1000]

Factor	Global	Sector	Tilt
PROFITABILITY	65	73	-8DRAG
MOMENTUM	44	34	+10ALPHA
VALUATION	59	50	+9ALPHA
INVESTMENT	33	49	-16DRAG
STABILITY	72	74	-2NEUTRAL
SHORT INT	56	66	-10DRAG

Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.

Executive Summary

Our model assigns ALNYLAM PHARMACEUTICALS, INC. a Hold rating, with a composite score of 51.6/100 and 3 out of 5 stars. Ranked #1764 of 7,333 stocks, ALNY presents a mixed quantitative picture — neither compelling enough to initiate new positions nor weak enough to warrant selling. Investors already holding may consider maintaining their position while monitoring for changes in the factor profile.

Business Quality

ALNY earns a quality score of 65/100, indicating above-average business quality. The company reports a return on equity of 7.0% (sector avg: -1.9%), gross margins of 84.4% (sector avg: 44.1%), net margins of -3.5% (sector avg: 1.0%). Companies in this tier generally demonstrate consistent profitability and efficient capital deployment, though they may face some competitive pressure.

Intrinsic Valuation

ALNY's value score of 59/100 indicates the stock is fairly valued based on its current fundamentals. Key valuation metrics include a P/E ratio of 810.87x, an EV/EBITDA of 152.20x, a P/B ratio of 56.50x. At this level, neither a clear bargain nor overpriced, the stock's attractiveness depends more on forward growth expectations and qualitative factors.

Capital Reinvestment

ALNYLAM PHARMACEUTICALS, INC.'s investment score of 33/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of 89.3% vs. a sector average of 6.7% and a return on assets of 1.1% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.

Market Momentum

ALNY is currently showing below-average momentum at 44/100, which may indicate weakening institutional interest or negative sentiment shifts. Revenue growth stands at 89.3% year-over-year, while a beta of 0.87 reflects its sensitivity to broader market moves. Investors should note that declining momentum can precede further price weakness, though contrarian opportunities sometimes emerge at these levels.

Balance Sheet Health

ALNY shows good financial stability with a score of 72/100. Key stability metrics include a beta of 0.87 and a debt-to-equity ratio of 529.00x (sector avg: 0.2x). This suggests manageable leverage and moderate price volatility, making it appropriate for investors seeking a balance between growth potential and capital preservation.

Institutional Risk Profile

The short interest score of 56/100 for ALNY suggests somewhat elevated bearish positioning by institutional traders. Specific risk factors include elevated leverage (D/E: 529.00x). With a $59.8B market cap (large-cap), ALNYLAM PHARMACEUTICALS, INC. may experience above-average volatility. Investors should consider whether the short thesis has merit or if it creates a potential short-squeeze opportunity.

Sector Benchmark Analysis

ALNYLAM PHARMACEUTICALS, INC. is a large-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #1764 of 7,333 overall (76th percentile). Key comparisons include ROE of 7.0% exceeding the -1.9% sector median and operating margins of 3.8% above the 2.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.

Comparative Research Mesh

ALNY VS S&P 500 (SPY)TOP MANUFACTURING PEERS

Strategic Alternatives

While ALNY currently exhibits a HOLD profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.

View Top Manufacturing Alpha →

ALNY

ALNYLAM PHARMACEUTICALS, INC.

Business Summary

Operations

Location

Fundamental Spot Check

Valuation

Efficiency & Risk

Intelligence Feed

ALNYLAM PHARMACEUTICALS, INC. (ALNY) Is Wall Street's Safest Bet. What Could Go Wrong?

Alnylam to Webcast Presentation at TD Cowen 46th Annual Health Care Conference

Alnylam Pharmaceuticals (ALNY) Reports $3B 2025 Revenue Driven by 151% TTR Franchise Surge

This AI Infrastructure Stock Is 'Most Likely' To Be Added To S&P 500 In Q1 2026 According To Prediction Markets

GSK Strikes $1 Billion China RNA Deal

Unlock Valuation Tools

Unlock Financial Statements

Unlock Governance & Ownership

Unlock Factor Analysis

Unlock Investment Thesis

Lateral Comparison Mesh

Comments

Unlock Performance & Technicals

SEC Risk Factors

Economic Moat Audit

Economic Value Creation

Margin Superiority

Reinvestment Efficiency

Growth Durability

Financial Resilience

Uncertainty Audit

BEAR THESIS

01Executive Summary

02Strategy & Outlook

Risk / Reward Variance

Research Verdict

Related Stocks

Executive Summary

Business Quality

Intrinsic Valuation

Capital Reinvestment

Market Momentum

Balance Sheet Health

Institutional Risk Profile

Sector Benchmark Analysis

Comparative Research Mesh

Strategic Alternatives

Factor Dispersion Audit

Sector Variance Findings

Market Intel

Intelligence Feed

ALNYLAM PHARMACEUTICALS, INC. (ALNY) Is Wall Street's Safest Bet. What Could Go Wrong?

Alnylam to Webcast Presentation at TD Cowen 46th Annual Health Care Conference

Alnylam Pharmaceuticals (ALNY) Reports $3B 2025 Revenue Driven by 151% TTR Franchise Surge

This AI Infrastructure Stock Is 'Most Likely' To Be Added To S&P 500 In Q1 2026 According To Prediction Markets

GSK Strikes $1 Billion China RNA Deal